Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma

Medical Hypotheses

Volumn 62, Issue 5, 2004, Pages 817-818

  Kast, Richard E ^a   Altschuler, Eric Lewin ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIHISTAMINIC AGENT; DESIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NITRIC OXIDE; PAROXETINE; QUETIAPINE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR;

ADJUVANT THERAPY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PSORIASIS; SHORT SURVEY;

EID: 1942532040     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.032     Document Type: Article

References (12)

1. Kumar A, Loughran T, Alsina M, Dune BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293-304.
2. Börset MW, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994;33:31-7.
3. Klein B, Zhang XG, Content J, Houssiau F, Aedern L, Piechaczyk M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin 6. Blood 1989;73:517-26.
4. Conti P, Kemparuj D, Di Gioacchino M, et al. Interleukin-6 and mast cells. Allergy Asthma Proc 2002;23:331-5.
5. Miljkovic DJ, Samardzic T, Drakulic D, Stosic-Grujicic S, Trajkovic V. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast Il-6 production by distinct mechanisms. Cytokine 2002;19:181-6.
6. Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion. Gastroenterology 2001;121:1260-1.
7. Kast RE. Crohn's disease remission with phenelzine treatment. Gastroenterology 1998;115:1034-5.
8. Talmadge J, Scott R, Castelli P, Newman-Tarr T, Lee J. Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells. Int J Immunopharmacol 1993;15:219-28.
9. Guirao X, Kumar A, Katz J, Smith M, Lin E, Keogh C, et al. Catecholamines increase monocyte TNF receptors and inhibit TNF through (β-2 adrenoreceptor activation. Am J Physiol 1997;273:E1203-1208.
10. Modell JG, Boyce S, Taylor E, Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with buproplon-SR: a pilot study. Psychosom Med 2002;64:835-40.
11. Finkel MS, Laghrissl-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-8.
12. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39.